
The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.
Barbara Burtness, MD, discusses immune checkpoint inhibitors for head and neck cancers.
about 12 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerabout 12 years ago
Sequencing Sorafenib and Lenvatinib in Thyroid Cancerabout 12 years ago
The Side Effects of Lenvatinibabout 12 years ago
Battling the Immunosuppressive Nature of Head and Neck Cancer
